Top Image
Advanced Centre for Treatment Research & Education in Cancer
Facebook Twitter Gmail
Banner Image
Science Sparks @ ACTREC
Date Image 25 January 2021 Vol. No. 10; Issue No. 459

1. Jose J, Al-Dorzi HM, Al-Omari A, Mandourah Y, Al-Hameed F, Sadat M, Al Qasim E, Alraddadi B, Al Harthy A, Al Mekhlafi GA, Almotairi A, Al Khatib K, Abdulmomen A, Qushmaq I, Sindi AA, Mady A, Solaiman O, Al-Raddadi R, Maghrabi K, Ragab A, Kharaba A, Shalhoub S, Al-Aithan AM, Vishwakarma GK, Bhattacharjee A, Arabi YM; Saudi Critical Care Trials Group (2021). Critically ill patients with diabetes and Middle East respiratory syndrome: a multi-center observational study. BMC Infectious Diseases. 21(1): 84.

2. Iwasaki K, Araki A, CM Krishna, Maruyama R, Yamamoto T, Noothalapati H (2021). Identification of molecular basis for objective discrimination of breast cancer cells (MCF-7) from normal human mammary epithelial cells by Raman Microspectroscopy and multivariate curve resolution analysis. International Journal of Molecular Sciences. 22(2): 800.

3. Desai S, Rashmi S, Rane A, Dharavath B, Sawant A, Dutt A (2021). An integrated approach to determine the abundance, mutation rate and phylogeny of the SARS-CoV-2 genome. Briefings in Bioinformatics.

4. Joshi S, Jaiswal D, Chougle Q, Wadasadawala T, Badwe R (2020). Transposition flap for the oncoplastic reconstruction of outer quadrant breast defects. . Journal of Plastic, Reconstructive & Aesthetic Surgery.

Bhattacharjee A. Bayesian Approches in Oncology Using R and Openbugs. 1st ed. Florida: CRC Press, 2021. (ISBN: 978-0-367-35050-5)

Site of the Week

Chemical Entities of Biological Interest (ChEBI) is a freely available dictionary of molecular entities focused on ‘small’ chemical compounds.

desktop Image
Interesting Reads

Pastushenko I, Mauri F, Song Y, de Cock F, Meeusen B, Swedlund B, Impens F, Van Haver D, Opitz M, Thery M, Bareche Y, Lapouge G, Vermeersch M, Van Eycke YR, Balsat C, Decaestecker C, Sokolow Y, Hassid S, Perez-Bustillo A, Agreda-Moreno B, Rios-Buceta L, Jaen P, Redondo P, Sieira-Gil R, Millan-Cayetano JF, Sanmatrtin O, D'Haene N, Moers V, Rozzi M, Blondeau J, Lemaire S, Scozzaro S, Janssens V, De Troya M, Dubois C, Pérez-Morga D, Salmon I, Sotiriou C, Helmbacher F, Blanpain C. Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis. Nature. 589(7842):448-455, 2021.

Legends of Science
Rudolf Ludwig Carl Virchow Girindra Sekhar Bose

Bose obtained his DSc from the University of Calcutta (1921). He specialized in Psychoanalysis and Psychology. He mastered the technique of hypnotism to treat the mental patients. He helped surgeons by putting the patient in hypnotic trance. He made his own investigations into the unconscious regions of the mind. In General Psychology, he made a number of original contributions. He pioneered the Mental Hygiene Movement in India. He established the first Mental Diseases Department in the Carmichael Medical College. Bose was the President, Psychology Section of the Indian Science Congress (1933). He was the founder of the Indian Psychoanalytical Society.

Andreas Vesalius Maharaj Kishan Bhan

Maharaj Kishan Bhan was pediatrician. He obtained his M.D. from Post Graduate Institute of Medical Education and Research, Chandigarh. His areas of research were diarrheal diseases and child nutrition with an emphasis on public health issues. In collaboration with Bharat Biotech International, he developed Rota Viral Vaccine. Bhan conceived the newly formed BIRAC, which is expected to result in product development by industry in collaboration with academia. He served as the president of the Jawaharlal Nehru Institute of Postgraduate Medical Education & Research (JIPMER). He was positioned as Secretary, Department of Biotechnology, Government of India, until 2012. He was awarded the Shanti Swarup Bhatnagar Prize for Science and Technology (1990), Padma Bhushan (2013). He was Member of the Jury for nearly all major national science awards awarded by the Government of India.

Do You Know?

In 2004, Azacitidine, an inhibitor of DNA methylation and a pioneering epigenetic therapy, became the first drug to gain US Food and Drug Administration (FDA) approval for the treatment of myelodysplastic syndrome.

back Image
Cancer News
Researchers identify how cancer cells adapt to survive harsh tumor microenvironments

19 January 2021, ScienceDaily

To better understand the conditions that select for the Warburg Effect and the mechanisms where cells can express this metabolic adaptation, researchers subjected nonmalignant cells to the harsh tumor microenvironment that is present during early carcinogenesis, known as ductal carcinoma in situ…

Designer DNA therapeutic wipes out cancer stem cells, treats multiple myeloma in mice

20 January 2021, EurekAlert

Researchers at University of California San Diego School of Medicine and Ionis Pharmaceuticals are taking a new, targeted approach to myeloma treatment -- silencing IRF4, a gene that allows myeloma stem cells and tumor cells to proliferate and survive...

New study helps understand molecular profile of tumors in cancer patients

21 January 2021,

The "Tumor Profiler" project aims to derive the comprehensive molecular profile of tumors in cancer patients, which has the potential to predict the efficacy of a host of new cancer medications. It will therefore make it possible to offer treating physicians personalized and improved therapy recommendations…

� 2021 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)